Clinical Trial Update: A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease [Phase 3]

View source ↗

Summary

Phase 3 trial of sodium oligomannate (GV-971) in mild to moderate Alzheimer's disease is suspended.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Sodium oligomannate (sodium oligomannate)

Snippet

Sponsor: Green Valley (Shanghai) Pharmaceuticals Co., Ltd. | Conditions: Alzheimer Disease | Phase 3 | Status: SUSPENDED